We show that, before initiation of treatment of “cold” tumors, intratumoral heterogeneity of the distribution of CD4 + or CD8 + T cells at baseline, not the total number of T cells, is predictive of immunotherapy outcomes in these mouse breast cancer models. Here, CD8A is linked to breast carcinoma.